SK bioscience announced on the 30th that the company’s next-generation pneumococcal conjugate vaccine (PCV) co-developed with Sanofi Pasteur was submitted to an IND amendment for a Phase II clinical trial in the United States’ regulatory agency last month.

In 2014, SK chemicals signed an agreement with Sanofi Pasteur to jointly develop and commercialize an innovative vaccine against pneumococcal infection. In the end of 2019, a non-refundable 11 million USD was paid to SK bioscience upon successful completion of a Phase I clinical trial.

The global pneumococcal conjugate vaccine market reached the size of USD 6.3 billion in 2017. This market is expected to grow to the size of 9 billion USD by 2025

(Source: Allied Market Research, published on May, 2019).

Jaeyong Ahn, CEO of SK bioscience said, “A vaccine that will create high added value in the global market has been developed with domestic technology and is gradually approaching success. We will finish the rest of the Phases II and Phase III clinical trials to achieve the positive result.